Abstract:Funding Acknowledgements Type of funding sources: Public grant(s) – EU funding. Main funding source(s): European Innovation Council Eurostars Background Cardiac gene transfer utilizing adeno-associated virus (AAV) is a promising approach for the treatment of various cardiovascular diseases. Intramyocardial injection is an efficient delivery route, and is particularly relevant for ischemic disease or pacemaker and conduction system abnormalities, where local treatment is favoured. However, which AAV variants provide efficient cardiac gene transfer after intramyocardial injection remains to be tested. Aim This study aims to compare several cardiotropic AAV variants in order to identify their relative potency in the setting of direct intramyocardial injection. Methods A green fluorescent protein (GFP)-coding sequence was packaged in the two benchmark AAV capsids, AAV6 and AAV9, and a selection of recently reported AAV9 capsid variants which are named MyoAAVs. These AAV vectors were added to neonatal rat ventricular cardiomyocytes (NRVM) and their transduction efficiency was evaluated by flow cytometry and quantitative PCR. AAV6, AAV9 and MyoAAV4A vectors were then delivered into the left ventricle of FVB mice via intramyocardial injection. AAV6 and AAV9 carrying GFP in a different expression cassette were also intramyocardially injected in FVB and Bl6 mice. Direct fluorescence, transgene mRNA, and viral genomes were quantified to determine the transduction efficiency 4 weeks post injection. Picrosirius red staining was used to assess whether AAV-mediated GFP delivery causes cardiac fibrosis. We further studied GFP encoding AAV6 and AAV9 vectors upon intramyocardial injection into the left ventricle of pigs and determined the transduction efficiency by quantitative PCR. Results NRVM transduction experiment revealed that among the tested capsid variants, AAV6 is the most efficient in transducing cardiomyocytes, followed by MyoAAV4A. In mice, AAV6 is most effective in transducing myocardium upon intramyocardial injection, resulting in approximately 10-fold higher transgene expression than that obtained with AAV9 vector and 2-fold higher than that with MyoAAV4A vector. Histology revealed no vector-related cardiac fibrosis. The use of different expression cassettes and animal strains consistently showed that AAV6 outperforms AAV9 in cardiac transduction efficiency. Transgene expression in liver was only observed in Bl6 mice injected with AAV9. In porcine myocardium, AAV6 led to robust transgene expression after intramyocardial injection and this expression level is higher than that of AAV9. Conclusion Among the AAV variants tested, AAV6 appears to be the most efficient for cardiac transduction by intramyocardial injection. These results suggest that AAV6 represents an attractive vector for direct cardiac gene transfer and for future capsid engineering in the context of local transgene delivery.

Myocardial infarction creates a critical time window for AAV gene therapy

Myocardial Infarction Creates a Critical Time Window for AAV-based Cardiac Gene Transfer

Raav-Mediated Angiogenin Gene Transfer Induces Angiogenesis and Modifies Left Ventricular Remodeling in Rats with Myocardial Infarction

Angiogenin Gene Transfer Improves Left Ventricular Function in Rats with Myocardial Infarction

AAV-mediated gene therapy: Advancing cardiovascular disease treatment

Intramyocardial Injection of Recombinant Adeno-Associated Viral Vector Coexpressing PR39/Adrenomedullin Enhances Angiogenesis and Reduces Apoptosis in a Rat Myocardial Infarction Model

Effects of Adenovirus-mediated VEGF165 Gene Therapy on Myocardial Infarction.

Recombinant Adeno-Associated Viral Vector 2-Mediated Gene Transfer of VEGF165 Improved Porcine Chronic Myocardial Ischemia

Coexpression Of Vegf And Angiopoietin-1 Promotes Angiogenesis And Cardiomyocyte Proliferation Reduces Apoptosis In Porcine Myocardial Infarction (Mi) Heart

Adeno-associated virus (AAV) 6 provides efficient gene transfer upon intramyocardial injection in vivo

Abstract 11471: Engineered Bacterial Sodium Channel Gene Therapy Prevents Contractile Deficit and Reduces Ventricular Arrhythmias in a Non-Human Primate Model of Myocardial Infarction

GW24-e2389 Delivery of AAV9 Cyclin-A2 Via Hyaluronic Acid Hydrogel Induces Cardiac Regeneration As Well As Improves Cardiac Functionin Vivopost Mycardial Infarction

Raav-Mediated VEGF Gene Transfer Induces Neovascular Formation in a Rabbit Myocardial Ischemic Model

Efficacy and safety of myocardial gene transfer of adenovirus, adeno-associated virus and lentivirus vectors in the mouse heart

AAV-mediated gene delivery to the cardiac conduction system

In vivo combinatory gene therapy synergistically promotes cardiac function and vascular regeneration following myocardial infarction

Extracellular Vesicle-Encapsulated Adeno-Associated Viruses for Therapeutic Gene Delivery to the Heart

AAV Gene Transfer to the Heart

Adeno-Associated Virus-mediated Gene Therapy for Cardiac Tachyarrhythmia: A Systematic Review and Meta-analysis

Elabela gene therapy promotes angiogenesis after myocardial infarction

Targeted Delivery of Human VEGF Gene Via Complexes of Magnetic Nanoparticle-Adenoviral Vectors Enhanced Cardiac Regeneration